A pill instead of an injection? New GLP-1 pill shows promising results in diabetes

Embargoed until: Publicly released: 2025-06-23 16:10

International

Image by Anna from Pixabay

A new drug, which can be taken as a pill and is in the same class of drugs as Ozempic, has shown promise for blood sugar control in clinical trials. The drug, orforglipron, is a glucagon-like peptide-1 (GLP-1) receptor agonist, which shows significant and clinically meaningful improvements in blood sugar control over 40 weeks and reduces body weight by up to 7.6%. The authors say the size of the effect on blood sugar was consistent with results from previous trials of oral and injectable GLP-1 receptor agonists.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Media Release Eli Lilly, Web page

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Velocity Clinical Research Center at Medical City Dallas, USA

Funder: Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940

Media Contact/s

Contact details are only visible to registered journalists.